Morgan Stanley initiated coverage of Novo Nordisk (NVO) with an Equal Weight rating and DKK 700 price target The firm says near-term U.S.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

By contrast, Novo Nordisk is both the developer and seller of Wegovy, while Viking Therapeutics's VK2735 has posted impressive results in testing and is now in the later stages of development. Wegovy ...

Welcome to the full-year 2024 Novo Nordisk earnings conference call. [Operator instructions] Please be advised that today's conference is being recorded. I would now like to hand the conference over ...

VANCOUVER, British Columbia and PERTH, Australia, Feb. 05, 2025 (GLOBE NEWSWIRE) -- HIGHLIGHTS – FOURTH QUARTERThree new high ...

The US Food and Drug Administration (FDA) has approved Novo Nordisk's Ozempic to lower the risk of kidney failure and disease progression. According to a statement made by the Danish ...

G/O Media is once again attempting to use AI to churn out content — while simultaneously warning that anything the AI ...

The Food and Drug Administration approved Novo Nordisk's Ozempic for patients with ... and death among patients with end-stage kidney disease is "very high," particularly from cardiovascular ...

Novo Nordisk and Eli Lilly have filed a motion to dismiss in the MDL over Ozempic and similar drugs. The defendants are asking the court to throw out 12 of the plaintiffs' 17 claims. The ...

Patients to pay no more than $35 a month Eli Lilly, Sanofi previously settled overcharging claims Novo Nordisk ... high prices for the diabetes drug. It requires Novo Nordisk to cap out-of-pocket ...